68Ga-PFA2 PET scan to detect Annexin A2‑positive tumors
Official title: PET Imaging Study of 68Ga-PFA2 Probe for Annexin A2-Positive Tumors
Run by Peking University First Hospital · NCT07331532 · Data updated 2026-11-12
This will try a new 68Ga‑PFA2 PET scan to see if it can detect Annexin A2‑positive tumors in adults with breast, lung, or pancreatic cancer.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 10 (estimated) |
| Sponsor | Peking University First Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Status | Recruiting |
| Started | June 1, 2025 |
| Main results expected | October 1, 2027 |
| Study ends | October 1, 2027 |
| Registry record updated | January 20, 2026 |
| Trial ID | NCT07331532 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Enrollment is limited to adults aged 18–80 with confirmed lung cancer who are scheduled for pathological biopsy or surgical treatment within the next two months and who can give informed consent.
✕Probably not a fit
Patients who have contraindications to PET/CT or to 68Ga‑PFA2 administration, those with other active malignancies or severe comorbidities, cognitive impairment preventing consent, or who fall outside the 18–80 age range are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a single‑site observational imaging project using a novel radiotracer, 68Ga‑PFA2, that binds Annexin A2 to highlight tumor invasion and metastasis. Enrolled participants will undergo 68Ga‑PFA2 PET/CT imaging and results will be compared with standard imaging, pathology from planned biopsies or surgeries, and clinical follow‑up. The goal is to characterize tracer uptake patterns in Annexin A2‑positive tumors and determine whether the imaging provides additional information about metastatic spread beyond current methods. No investigational treatment is given; the protocol focuses on image acquisition and correlation with existing diagnostic data.
Why it matters
Potential benefit: If successful, the scan could allow earlier or more accurate detection of invasive or metastatic disease and help doctors tailor treatment plans.
How similar studies have gone: Targeted PET tracers for other tumor markers (for example PSMA or HER2 tracers) have shown clinical value, but Annexin A2‑targeted imaging is relatively novel with limited published human data so far.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged 18-80 years. * Diagnosed with confirmed lung cancer. * Scheduled to undergo pathological tissue biopsy or surgical treatment within the next two months. * Able to fully comprehend and voluntarily participate in the study. * Able to provide informed consent. * Capable of cooperating independently to complete the examinations. Exclusion Criteria: * Patients with other malignancies or severe comorbidities that affect their ability to participate. * Patients unable to provide informed consent due to cognitive impairment. * Patients with contraindications to PET/CT scans or 68Ga-PFA2 administration.
Where it's running
-
Peking university first hospital nuclear medicine
Beijing, Beijing Municipality, China Recruiting
Study contacts
- Study coordinator: Tingting Yuan
- Email: biluohtt@163.com
- Phone: +86-13051707479
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.